·§©À¸Ñ½X¡GÃĪ«±M§QÅv
patenting of drugs
¡i©ú³ø±M°T¡jÃĪ«±M§Qªºì·N¬°«OÅ@Ãļt¬ãµo¥X·sÃĪºª¾ÃѲ£Åv¡A¦]¬ã»s·sÃįA¤Î¥¨ÃB§ë¸ê¡C®Ú¾Ú¥@¬É¶T©ö²Õ´q¥ßªº¡m»P¶T©ö¦³Ãöªºª¾ÃѲ£Åv¨óij¡n(Agreement on Trade-Related Aspects of Intellectual Property Rights, TRIPS)¡AÃļt¥i¬°¬ãµo¤Î»sÃĪº¹Lµ{©M¦¨«~¥Ó½Ð±M§Q¡A´Á¬°³Ì¤Ö20¦~¡C±M§QÅv«O»Ùì¬ãµoÃļt¨É¦³¿W®a¥Í²£Åv¡A¸T¤î¨ä¥LÃļt½Æ»s©Î¥é»s¡A¦P®É¸T¤î¥@¶T¦¨û°ê¶i¤f¥é»sÃĪ«(generic drugs¡A©ÎºÙ¦P¦WÃĪ«)¡A¤£¹L³Ì§C«×µo®i°ê®a¦]t¾á±M§QÃĪº°ªÃÄ»ù¦³§xÃø¡A¥i©µ«á¹ê¬I¨î¤J¤fªº³W¨Ò¡C¦pµo²{¥é»sÃĪ«¡AÃļt¥i¥H´£¥X¥Á¨Æ¶D³^¡A¸T¤î«IÅv¦æ¬°¡C±M§Q´Á¹L«áÃļt¶·¤½¶}°t¤è¡A¨ä¥LÃļt¥i¨Ì°t¤è°t»sÃĪ«¡A§Y¥é»sÃÄ¡C¦Ó¥é»sÃÄ»ù®æ¤ñ±M§QÃÄ(patent drugs)«K©y±o¦h¡A¸û©öt¾á¡C
¡½¤½¦@½Ã¥Í
¦³§U¼úÀyµo©ú
Ãļt¬ãµoÃĪ«¦hn¥¨ÃB§ë¸ê©M©Ó¾á°ª·ÀI¡A±M§Q¨î«×ÅýÃļt¦¬¦^¬ã»s¦¨¥»¡A¤]¥i¸É¶K¹Lµ{¤¤¬ãµo¥¢±Ñªº¦¨¥»¡A¨Ò¦p¨Ã«D¨CºØÃij£¥i¥H³q¹LÁ{þH´ú¸Õ¡A¦Ó³q¹LÁ{þH´ú¸ÕÃÒ©ú¬O¦w¥þ¥B¦³®Ä«á¡A¥çn±o¨ì¬ÛÃö¬F©²ÃĪ«ºÞ²z§½ªº»{¥i¡A¤~¯à±À¥X¥«³õ¡C¤¤¤jÃľ¯¾Ç°|°Æ±Ð±Â§õµú®¦«ü¥X¡A¤@¯ë¨Ó»¡·sÃĤñÂÂÃĶQ¡A·sÃıM§Q´Á¶¡Ãļt¿WÉ]»sÃÄ¡A½Õ°ª©w»ù¥H¸É¶K¬ãµo¦¨¥»¡C¦oªí¥Ü¬ãµo¤@ºØÃÄ°Ê»³10¦~¡A·í¤¤¯A¤Îªºª÷ÃB¥H»õ¸U´ä¤¸p¡C¦ÓÀò±o±M§QÅv·N¨ý¦³°ªÃÄ»ùªº¦^³ø¡A¹ªÀyÃļt§ë¸ê¨Ã¬ãµo·sÃÄ¡CÃĪ«°â»ù·U°ª¡A§Q¼í·UÂ׫p¡C
¡½¥þ²y¤Æ¡Ñ¤½¦@½Ã¥Í
¥é»sÃĪ«ª§Ä³
±M§QÅv®É¹L«á¡A¨ä¥L¦X¸ê®æªºÃļt¥i¥Í²£¬Û¦P¦¨¤ÀªºÃÄ«~¡A¥ç§Y¥é»sÃÄ¡A¦ý¤£¯à¨Ï¥Î¦P¤@°Ó·~¦WºÙ¡C¥é»sÃĪº¨Ï¥Î¤èªk¡B¾¯¶q¤ÎªvÀø¥Î³~¸òì¼tÃĤ@¼Ë¡A¦ý»s³y¤èªk«h¥i¤£¦P¡A»ù¿ú³q±`¸û«K©y¡C¬ü°ê¤@ºØ§í¨îG»Ä¤Àªcªº±M§QÃĪ«Omeprazole¡A¨C²É°â»ù3.76¬ü¤¸¡A¦ý¦L«×ªº¥é»sÃÄ¥u»Ý0.09¬ü¤¸¡A»ù®æ¬Û®tªñ40¿¡C¦b·sÃĪº±M§Q´Á¹L«á¡A¨ä¥LÃļt¥i¥H¥Î¬Û¦Pªº¤èµ{¦¡¥Í²£¥é»sÃÄ¡A¦]¬°¦³Ävª§¡AÃĪ«»ù®æ¤@¯ë·|¤U°¡C
1998¦~¡A«n«Dªº·R´þ·P¬V²v°ª¹F22.8%¡A¦ý¤H¥Á¤Î¬F©²³£¨S¦³¨¬°÷¸êª÷ÁʶR³Q»{¬°Àø®Ä³Ì¨Îªº¡uÂû§À°sÀøªk¡v±M§QÃÄ¡A¦]³oÃĨC¤H¨C¦~ªº¦¨¥»°ª¹F1¸U¦Ü1.5¸U¬ü¤¸¡C¦]¦¹·í¦a¬F©²¨Ï¥Î¦¨¥»¥u»Ý¬ù350¬ü¤¸¡B¨Ó¦Û¦L«×ªº¥é»sÃÄ¡C¦P¦~39¶¡¸ó°ê¤jÃļtÁp¦X±±§i«n«D¬F©²«I¥Çª¾ÃѲ£Åv©M¬»Ä²¤FTRIPS¡A¤Þ¨Ó·¥¤j°jÅT¡CÁöµM©Ò¦³Ãļt©ó2001¦~ºM¾P°_¶D¡A¦ý¶D³^´Á¶¡«n«D°±¥Î¥é»sÃÄ¡A¥O¤j¶q¤H¦º©ó·R´þ¬ÛÃöªº¯e¯f¡C
³h½a°ê®a¶R¤£°_¶QÃÄ
¥þ²y¤Æ¤U¡A¦U¦a¥æ¬yÀWÁc¡A¯f¬rµ¥¥ç¥iÀH¤H̪º¸ó¹Ò¬¡°Ê¦Ó¶Ç¼½¨ì¦U¦a¡AÀH®ÉÃzµo¤j³W¼Ò¬Ì¯g¡Cµo¹F°êªÀ·|ÂåÀøºÖ§Q¨î«×¸û§¹µ½¡A¯f¤Hªº³¡¤ÀÂåÀø¶}¤ä¥Ñ¤½¦@°]¬F©Î¨p¤H«OÀIt¾á¡F¦Ó¤£¤Öµo®i¤¤°ê®a¥¼¦³°·¥þªº¤½¦@°]¬F¡A¤½¦@ÂåÀøªº§ë¤J¬Û¹ï¦a§C¡A¯f¤Hn¦Û¦æt¾á¤j³¡¤ÀÃĶO¡A¹ï·G»ùÃĪ«ªº»Ý¨D¬Æ¤j¡C®Ú¾Ú¼Ö¬I·|ªº¸ê®Æ¡Aµá«ß»«¬F©²³q¹L¤F¡m»ù·G½èÀuÃÄ«~¥þ±¬y³qªk2008¡n¡A¤H¥Á¥i¨É¥Î³¡¤À¥Ñ¤Ú°ò´µ©Z¥Í²£ªºÃĪ«¡AÃĮĬۦP¡A¦ý»ù¿ú§C·G±o¦h¡C±ø¤å½á¤©¬F©²·sÅv¤O¡A¤£¨üÃÄ°ÓªºÃĪ«±M§Q¯SÅv¨î¡A¥i¦b¥@¬É¦U¦a¤J¤f»ù·GªºÃĪ«¡C
µL°ê¬ÉÂå¥Í¦b¦hÓµo®i¤¤°ê®a¬°10¸Up·R´þ¯f±wªÌ´£¨ÑªvÀø¡A´£¨Ñ»ù®æ¬Û©yªº¥é»sÃÄ¡C·í¯f¤H±µ¨üªvÀø¤@¬q®É¶¡«á¡A©Î·|¹ïªA¥Î¤¤ªºÃĪ«²£¥Í@ÃÄ©Ê¡A¦]¦¹¦³»Ýn©w®ÉÂàªA·sÃÄ¡A¦ý³o¨ÇÃĪ«©¹©¹¸û©ù¶Q¡C©Ò¥HµL°ê¬ÉÂå¥Í¦Û2006¦~°_¡A¤@ª½±À°Ê¦¨¥ß¡u±M§Q¦À¡v¡CÃĪ«±M§Q¦À¦®¦b³z¹L¦V±M§Q«ù¦³¤H¥I¶O¡A®e³\¥é»sÃļt¥Í²£§t±M§QÅvªºÃĪ«¡A¬°µo®i¤¤°ê®a´£¨Ñ¸û«K©yªºÃĪ«¡CÃĪ«±M§Q¦À©ó2010¦~7¤ë¥¿¦¡¦¨¥ß¡A±À°Êµo®i¤¤°ê®aÀò±o»ù®æ¬Û©yªºÃĪ«¡C±M§Q¦À¦¨¥ß«á¨âÓ¤ë¡AÀò±o¬ü°ê°ê®a½Ã¥Í°|(NIH)ªº¥¿¦¡¤ä«ù¡A±N·R´þ¯fÃĪ«Darunavirªº±M§Q¥æ¥ÑÃĪ«±M§Q¦À³B²z¥H§@¤ä«ù¡C